首页 > 最新文献

Radiotherapy and Oncology最新文献

英文 中文
The Assisi think tank focus review on postoperative radiation for lobular breast cancer 阿西西智囊团对乳腺小叶癌术后放射治疗的重点审查。
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-11 DOI: 10.1016/j.radonc.2024.110573
O. Kaidar-Person , I Ratosa , P. Franco , V. Masiello , F. Marazzi , S. Pedretti , A. Ciabattoni , M.C. Leonardi , T. Tramm , CE Coles , I Meattini , M. Arenas , B.V. Offersen , L.J. Boersma , V. Valentini , D. Dodwell , P. Poortmans , C. Aristei
The “Assisi Think Tank Meeting” (ATTM) on Breast Cancer, endorsed by the European Society for Radiotherapy & Oncology (ESTRO) and the Italian Association of Radiotherapy and Clinical Oncology (AIRO), and conducted under the auspices of the European Society of Breast Cancer Specialists (EUSOMA), is a bi-annual meeting aiming to identify major clinical challenges in breast cancer radiation therapy (RT) and proposing clinical trials to address them. The topics discussed at the meeting are pre-selected by the steering committee. At the meeting, these topics are discussed in different working groups (WG), after preparation of the meeting by performing a systematic review of existing data and of ongoing trials. Prior to the meeting, each WG designs a survey on the topic to be discussed to reflect current clinical practice and to identify areas requiring further research. Herein, we present the work done by the Assisi WG focusing on lobular carcinoma and the RT perspectives in its treatment, including providing recommendations for locoregional therapy, mainly RT for patients with non-metastatic lobular breast cancer.
乳腺癌 "阿西西智囊团会议"(ATM)由欧洲放射治疗与肿瘤学会(ESTRO)和意大利放射治疗与临床肿瘤学会(AIRO)批准,在欧洲乳腺癌专家学会(EUSOMA)的支持下举行,是一年两次的会议,旨在确定乳腺癌放射治疗(RT)的主要临床挑战,并针对这些挑战提出临床试验建议。会议讨论的主题由指导委员会预先选定。在对现有数据和正在进行的试验进行系统回顾,为会议做准备后,这些议题将在不同的工作组(WG)中进行讨论。会前,每个工作组都会就讨论主题设计一份调查问卷,以反映当前的临床实践,并确定需要进一步研究的领域。在此,我们将介绍阿西西工作组所做的工作,重点是小叶癌及其治疗中的 RT 观点,包括为局部治疗提供建议,主要是针对非转移性小叶乳腺癌患者的 RT。
{"title":"The Assisi think tank focus review on postoperative radiation for lobular breast cancer","authors":"O. Kaidar-Person ,&nbsp;I Ratosa ,&nbsp;P. Franco ,&nbsp;V. Masiello ,&nbsp;F. Marazzi ,&nbsp;S. Pedretti ,&nbsp;A. Ciabattoni ,&nbsp;M.C. Leonardi ,&nbsp;T. Tramm ,&nbsp;CE Coles ,&nbsp;I Meattini ,&nbsp;M. Arenas ,&nbsp;B.V. Offersen ,&nbsp;L.J. Boersma ,&nbsp;V. Valentini ,&nbsp;D. Dodwell ,&nbsp;P. Poortmans ,&nbsp;C. Aristei","doi":"10.1016/j.radonc.2024.110573","DOIUrl":"10.1016/j.radonc.2024.110573","url":null,"abstract":"<div><div>The “Assisi Think Tank Meeting” (ATTM) on Breast Cancer, endorsed by the European Society for Radiotherapy &amp; Oncology (ESTRO) and the Italian Association of Radiotherapy and Clinical Oncology (AIRO), and conducted under the auspices of the European Society of Breast Cancer Specialists (EUSOMA), is a bi-annual meeting aiming to identify major clinical challenges in breast cancer radiation therapy (RT) and proposing clinical trials to address them. The topics discussed at the meeting are pre-selected by the steering committee. At the meeting, these topics are discussed in different working groups (WG), after preparation of the meeting by performing a systematic review of existing data and of ongoing trials. Prior to the meeting, each WG designs a survey on the topic to be discussed to reflect current clinical practice and to identify areas requiring further research. Herein, we present the work done by the Assisi WG focusing on lobular carcinoma and the RT perspectives in its treatment, including providing recommendations for locoregional therapy, mainly RT for patients with non-metastatic lobular breast cancer.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110573"},"PeriodicalIF":4.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hybrid ultra-high and conventional dose rate treatments with electrons and photons for the clinical transfer of FLASH-RT to deep-seated targets: A treatment planning study 利用电子和光子进行超高剂量率和常规剂量率混合治疗,将FLASH-RT应用于深部靶点的临床转移:治疗规划研究
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-11 DOI: 10.1016/j.radonc.2024.110576
Till Tobias Böhlen , Michele Zeverino , Jean‐François Germond , Rémy Kinj , Luis Schiappacasse , François Bochud , Fernanda Herrera , Jean Bourhis , Raphaël Moeckli

Purpose

This study explores the dosimetric feasibility and plan quality of hybrid ultra-high dose rate (UHDR) electron and conventional dose rate (CDR) photon (HUC) radiotherapy for treating deep-seated tumours with FLASH-RT.

Methods

HUC treatment planning was conducted optimizing a broad UHDR electron beam (between 20–250 MeV) combined with a CDR VMAT for a glioblastoma, a pancreatic cancer, and a prostate cancer case. HUC plans were based on clinical prescription and fractionation schemes and compared against clinically delivered plans. Considering a HUC boost treatment for the glioblastoma consisting of a 15-Gy-single-fraction UHDR electron boost supplemented with VMAT, two scenarios for FLASH sparing were assessed using FLASH-modifying-factor-weighted doses.

Results

For all three patient cases, HUC treatment plans demonstrated comparable dosimetric quality to clinical plans, with similar PTV coverage (V95% within 0.5 %), homogeneity, and critical OAR-sparing. At the same time, HUC plans delivered a substantial portion of the dose to the PTV (Dmedian of 50–69 %) and surrounding tissues at UHDR. For the HUC boost treatment of the glioblastoma, the first FLASH sparing scenario showed a moderate FLASH sparing magnitude (10 % for D2%,PTV) for the 15-Gy UHDR electron boost, while the second scenario indicated a more substantial sparing of brain tissues inside and outside the PTV (32 % for D2%,PTV, 31 % for D2%,Brain).

Conclusions

From a planning perspective, HUC treatments represent a feasible approach for delivering dosimetrically conformal UHDR treatments, potentially mitigating technical challenges associated with delivering conformal FLASH-RT for deep-seated tumours. While further research is needed to optimize HUC fractionation and delivery schemes for specific patient cohorts, HUC treatments offer a promising avenue for the clinical transfer of FLASH-RT.
目的 本研究探讨了超高剂量率(UHDR)电子和常规剂量率(CDR)光子混合放疗(HUC)的剂量学可行性和计划质量,以FLASH-RT治疗深部肿瘤。方法 对一例胶质母细胞瘤、一例胰腺癌和一例前列腺癌病例进行了超高剂量率电子束(20-250MeV)与常规剂量率光子混合放疗计划优化。HUC计划以临床处方和分层方案为基础,并与临床实施计划进行比较。结果在所有三个病例中,HUC 治疗计划的剂量质量与临床计划相当,具有相似的 PTV 覆盖率(V95% 在 0.5 % 以内)、均匀性和临界 OAR 保留率。同时,HUC 计划在 UHDR 时向 PTV(Dmedian 为 50-69%)和周围组织投放了大量剂量。对于胶质母细胞瘤的 HUC 增量治疗,第一种 FLASH 清除方案显示,15-Gy UHDR 电子增量对 FLASH 的清除程度适中(D2%,PTV 为 10%),而第二种方案显示对 PTV 内外的脑组织的清除程度更高(D2%,PTV 为 32%,D2%,Brain 为 31%)。结论从计划的角度来看,HUC 治疗是一种可行的方法,可用于进行剂量学保形 UHDR 治疗,从而有可能减轻与对深部肿瘤进行保形 FLASH-RT 治疗相关的技术挑战。虽然还需要进一步研究来优化针对特定患者群的 HUC 分层和给药方案,但 HUC 治疗为 FLASH-RT 的临床应用提供了一条前景广阔的途径。
{"title":"Hybrid ultra-high and conventional dose rate treatments with electrons and photons for the clinical transfer of FLASH-RT to deep-seated targets: A treatment planning study","authors":"Till Tobias Böhlen ,&nbsp;Michele Zeverino ,&nbsp;Jean‐François Germond ,&nbsp;Rémy Kinj ,&nbsp;Luis Schiappacasse ,&nbsp;François Bochud ,&nbsp;Fernanda Herrera ,&nbsp;Jean Bourhis ,&nbsp;Raphaël Moeckli","doi":"10.1016/j.radonc.2024.110576","DOIUrl":"10.1016/j.radonc.2024.110576","url":null,"abstract":"<div><h3>Purpose</h3><div>This study explores the dosimetric feasibility and plan quality of hybrid ultra-high dose rate (UHDR) electron and conventional dose rate (CDR) photon (HUC) radiotherapy for treating deep-seated tumours with FLASH-RT.</div></div><div><h3>Methods</h3><div>HUC treatment planning was conducted optimizing a broad UHDR electron beam (between 20–250 MeV) combined with a CDR VMAT for a glioblastoma, a pancreatic cancer, and a prostate cancer case. HUC plans were based on clinical prescription and fractionation schemes and compared against clinically delivered plans. Considering a HUC boost treatment for the glioblastoma consisting of a 15-Gy-single-fraction UHDR electron boost supplemented with VMAT, two scenarios for FLASH sparing were assessed using FLASH-modifying-factor-weighted doses.</div></div><div><h3>Results</h3><div>For all three patient cases, HUC treatment plans demonstrated comparable dosimetric quality to clinical plans, with similar PTV coverage (V<sub>95%</sub> within 0.5 %), homogeneity, and critical OAR-sparing. At the same time, HUC plans delivered a substantial portion of the dose to the PTV (D<sub>median</sub> of 50–69 %) and surrounding tissues at UHDR. For the HUC boost treatment of the glioblastoma, the first FLASH sparing scenario showed a moderate FLASH sparing magnitude (10 % for D<sub>2%,PTV</sub>) for the 15-Gy UHDR electron boost, while the second scenario indicated a more substantial sparing of brain tissues inside and outside the PTV (32 % for D<sub>2%,PTV</sub>, 31 % for D<sub>2%,Brain</sub>).</div></div><div><h3>Conclusions</h3><div>From a planning perspective, HUC treatments represent a feasible approach for delivering dosimetrically conformal UHDR treatments, potentially mitigating technical challenges associated with delivering conformal FLASH-RT for deep-seated tumours. While further research is needed to optimize HUC fractionation and delivery schemes for specific patient cohorts, HUC treatments offer a promising avenue for the clinical transfer of FLASH-RT.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110576"},"PeriodicalIF":4.9,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The significance of dose heterogeneity on the anti-tumor response of minibeam radiation therapy 剂量异质性对迷你束放射治疗抗肿瘤反应的意义。
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110577
Sarah Potiron , Lorea Iturri , Marjorie Juchaux , Julie Espenon , Cristèle Gilbert , Josie McGarrigle , Ramon Ortiz Catalan , Alfredo Fernandez-Rodriguez , Catherine Sebrié , Laurène Jourdain , Ludovic De Marzi , Gilles Créhange , Yolanda Prezado

Background and purpose

Proton Minibeam Radiation Therapy (pMBRT) is an unconventional radiation technique based on a strong modulation of the dose deposition. Due to its specific pattern, pMBRT involves several dosimetry (peak and valley doses, peak-to-valley dose ratio (PVDR)) and geometrical parameters (beam width, spacing) that can influence the biological response. This study aims at contributing to the efforts to deepen the comprehension of how the various parameters relate to central biological mechanisms, particularly anti-tumor immunity, and how these correlations affect treatment outcomes with the goal to fully unleash the potential of pMBRT. We also evaluated the effects of X-ray MBRT to further elucidate the influence of peak dose and dose heterogeneity.

Methods and Materials

An orthotopic rat model of glioblastoma underwent several pMBRT configurations. The impact of different dosimetric parameters on survival and on the modulation of crucial mechanisms for pMBRT, such as immune response, was investigated. The latter was assessed by immunohistochemistry and flow cytometry at 7 days post-irradiation.

Results

Survival was improved across the various pMBRT regimens via maintaining a minimum valley dose as well as a higher dose heterogeneity, which is driven by peak dose. While the mean dose did not impact immune infiltration, a higher PVDR promoted a less immunosuppressive microenvironment.

Conclusions

Our results suggest that both tumor eradication, and immune infiltration are associated with higher dose heterogeneity. Higher dose heterogeneity was achieved by optimizing the peak dose, as well as maintaining a minimum valley dose. These parameters contributed to direct tumor eradication as well as reduction of immunosuppression, which is a departure from the more immunosuppressive tumor environment found in conventional proton therapy that delivers uniform dose distributions.
背景和目的:质子微束放射治疗(pMBRT)是一种基于强剂量沉积调制的非常规放射技术。由于其特殊的模式,质子微束放射治疗涉及多个剂量测定(峰值和谷值剂量、峰谷剂量比(PVDR))和几何参数(束宽、间距),这些都会影响生物反应。本研究旨在加深对各种参数与中心生物机制(尤其是抗肿瘤免疫)之间的关系,以及这些关系如何影响治疗效果的理解,以充分发挥 pMBRT 的潜力。我们还评估了 X 射线 MBRT 的效果,以进一步阐明峰值剂量和剂量异质性的影响:方法和材料:对胶质母细胞瘤正位大鼠模型进行了多种 pMBRT 配置。研究了不同剂量参数对存活率的影响以及对 pMBRT 关键机制(如免疫反应)的调节。后者通过放射后7天的免疫组化和流式细胞术进行评估:结果:各种pMBRT方案通过保持最低谷剂量和更高的剂量异质性(由峰值剂量驱动)提高了生存率。虽然平均剂量对免疫浸润没有影响,但较高的PVDR可减少免疫抑制微环境:我们的研究结果表明,肿瘤根除和免疫浸润都与较高的剂量异质性有关。通过优化峰值剂量和保持最小谷值剂量,可以实现更高的剂量异质性。这些参数有助于直接根除肿瘤和减少免疫抑制,这与传统质子治疗中的均匀剂量分布所带来的免疫抑制性更强的肿瘤环境不同。
{"title":"The significance of dose heterogeneity on the anti-tumor response of minibeam radiation therapy","authors":"Sarah Potiron ,&nbsp;Lorea Iturri ,&nbsp;Marjorie Juchaux ,&nbsp;Julie Espenon ,&nbsp;Cristèle Gilbert ,&nbsp;Josie McGarrigle ,&nbsp;Ramon Ortiz Catalan ,&nbsp;Alfredo Fernandez-Rodriguez ,&nbsp;Catherine Sebrié ,&nbsp;Laurène Jourdain ,&nbsp;Ludovic De Marzi ,&nbsp;Gilles Créhange ,&nbsp;Yolanda Prezado","doi":"10.1016/j.radonc.2024.110577","DOIUrl":"10.1016/j.radonc.2024.110577","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Proton Minibeam Radiation Therapy (pMBRT) is an unconventional radiation technique based on a strong modulation of the dose deposition. Due to its specific pattern, pMBRT involves several dosimetry (peak and valley doses, peak-to-valley dose ratio (PVDR)) and geometrical parameters (beam width, spacing) that can influence the biological response. This study aims at contributing to the efforts to deepen the comprehension of how the various parameters relate to central biological mechanisms, particularly anti-tumor immunity, and how these correlations affect treatment outcomes with the goal to fully unleash the potential of pMBRT. We also evaluated the effects of X-ray MBRT to further elucidate the influence of peak dose and dose heterogeneity.</div></div><div><h3>Methods and Materials</h3><div>An orthotopic rat model of glioblastoma underwent several pMBRT configurations. The impact of different dosimetric parameters on survival and on the modulation of crucial mechanisms for pMBRT, such as immune response, was investigated. The latter was assessed by immunohistochemistry and flow cytometry at 7 days post-irradiation.</div></div><div><h3>Results</h3><div>Survival was improved across the various pMBRT regimens via maintaining a minimum valley dose as well as a higher dose heterogeneity, which is driven by peak dose. While the mean dose did not impact immune infiltration, a higher PVDR promoted a less immunosuppressive microenvironment.</div></div><div><h3>Conclusions</h3><div>Our results suggest that both tumor eradication, and immune infiltration are associated with higher dose heterogeneity. Higher dose heterogeneity was achieved by optimizing the peak dose, as well as maintaining a minimum valley dose. These parameters contributed to direct tumor eradication as well as reduction of immunosuppression, which is a departure from the more immunosuppressive tumor environment found in conventional proton therapy that delivers uniform dose distributions.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110577"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overestimation of contralateral hilar lymph node metastasis in non-metastatic non-small cell lung cancer and its predictive model: HAM 高估非转移性非小细胞肺癌对侧肺门淋巴结转移及其预测模型HAM
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110575
Zan Hou , Xiaoping Lin , Baiqiang Dong , Zaishan Lin , Yuan Zhang , Xu Liu , Chenfei Wu , Qingqing Xu , Ying Wang , Keying Chen , Qiwen Li , Ming Chen

Background and purpose

Metastasis of non-metastatic non-small cell lung cancer (NMNSCLC) to contralateral hilar lymph nodes (CHLN) eliminates the opportunity for radical therapy. This study aims to analyze whether CHLN metastasis in NMNSCLC is commonly overestimated in clinical practice and to establish a predictive model for enhanced precision.

Methods and materials

We conducted a retrospective analysis of 834 pathologically confirmed NMNSCLC patients. Monitoring of treatment responses and regular ≥ 1 year CT follow-up was used to determine the nature of CHLN. Lasso regression was used to select predictive factors, and a multivariate binary logistic regression model (HAM) was constructed. Internal validation was performed using ten-fold cross-validation.

Results

The CHLN metastasis rate was 4.4% among the NMNSCLC patients. The positive predictive value (PPV) and sensitivity for PET-CT diagnosis were 36.8% and 67.5%, while for CT they are 44.8% and 70.2%, respectively. The five optimal predictive factors (emphysema or bullae, central-type lung cancer, short diameter of CHLN, calcification and SUVmax) were used to develop the HAM model. The Area under curve (AUC) values for PET-CT, CT, and HAM model were 0.81, 0.83, and 0.96, respectively. The F1 scores for PET-CT and CT were 0.48 and 0.55, respectively, while the maximum F1 score of our model was 0.73, with corresponding PPV and sensitivity of 66.7%, and 81.1%, respectively.

Conclusions

CHLN metastasis is rare in NMNSCLC patients. PET-CT diagnosis significantly overestimates CHLN metastasis and the HAM model improves clinical decision-making in this study. Prospective studies are needed to confirm these conclusions.
背景和目的非转移性非小细胞肺癌(NMNSCLC)转移至对侧肺门淋巴结(CHLN)将失去根治性治疗的机会。本研究旨在分析NMNSCLC的CHLN转移在临床实践中是否经常被高估,并建立一个提高精确度的预测模型。方法和材料我们对834例病理确诊的NMNSCLC患者进行了回顾性分析。通过监测治疗反应和定期≥1年的CT随访来确定CHLN的性质。采用拉索回归法选择预测因素,并构建了多变量二元逻辑回归模型(HAM)。结果NMNSCLC患者的CHLN转移率为4.4%。PET-CT 诊断的阳性预测值(PPV)和灵敏度分别为 36.8% 和 67.5%,而 CT 诊断的阳性预测值和灵敏度分别为 44.8% 和 70.2%。五个最佳预测因素(肺气肿或肺大泡、中心型肺癌、CHLN 短直径、钙化和 SUVmax)被用于建立 HAM 模型。PET-CT、CT 和 HAM 模型的曲线下面积(AUC)值分别为 0.81、0.83 和 0.96。PET-CT和CT的F1得分分别为0.48和0.55,而我们模型的最大F1得分为0.73,相应的PPV和灵敏度分别为66.7%和81.1%。在本研究中,PET-CT 诊断明显高估了 CHLN 转移,HAM 模型改善了临床决策。需要进行前瞻性研究来证实这些结论。
{"title":"Overestimation of contralateral hilar lymph node metastasis in non-metastatic non-small cell lung cancer and its predictive model: HAM","authors":"Zan Hou ,&nbsp;Xiaoping Lin ,&nbsp;Baiqiang Dong ,&nbsp;Zaishan Lin ,&nbsp;Yuan Zhang ,&nbsp;Xu Liu ,&nbsp;Chenfei Wu ,&nbsp;Qingqing Xu ,&nbsp;Ying Wang ,&nbsp;Keying Chen ,&nbsp;Qiwen Li ,&nbsp;Ming Chen","doi":"10.1016/j.radonc.2024.110575","DOIUrl":"10.1016/j.radonc.2024.110575","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Metastasis of non-metastatic non-small cell lung cancer (NMNSCLC) to contralateral hilar lymph nodes (CHLN) eliminates the opportunity for radical therapy. This study aims to analyze whether CHLN metastasis in NMNSCLC is commonly overestimated in clinical practice and to establish a predictive model for enhanced precision.</div></div><div><h3>Methods and materials</h3><div>We conducted a retrospective analysis of 834 pathologically confirmed NMNSCLC patients. Monitoring of treatment responses and regular ≥ 1 year CT follow-up was used to determine the nature of CHLN. Lasso regression was used to select predictive factors, and a multivariate binary logistic regression model (HAM) was constructed. Internal validation was performed using ten-fold cross-validation.</div></div><div><h3>Results</h3><div>The CHLN metastasis rate was 4.4% among the NMNSCLC patients. The positive predictive value (PPV) and sensitivity for PET-CT diagnosis were 36.8% and 67.5%, while for CT they are 44.8% and 70.2%, respectively. The five optimal predictive factors (emphysema or bullae, central-type lung cancer, short diameter of CHLN, calcification and SUVmax) were used to develop the HAM model. The Area under curve (AUC) values for PET-CT, CT, and HAM model were 0.81, 0.83, and 0.96, respectively. The F1 scores for PET-CT and CT were 0.48 and 0.55, respectively, while the maximum F1 score of our model was 0.73, with corresponding PPV and sensitivity of 66.7%, and 81.1%, respectively.</div></div><div><h3>Conclusions</h3><div>CHLN metastasis is rare in NMNSCLC patients. PET-CT diagnosis significantly overestimates CHLN metastasis and the HAM model improves clinical decision-making in this study. Prospective studies are needed to confirm these conclusions.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110575"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers 头颈部癌症图像引导质子治疗中患者直立定位重现性研究
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110572
J. Feldman , A. Pryanichnikov , D. Shwartz , Y. Hillman , M. Wygoda , P. Blumenfeld , M. Marash , A. Popovtzer

Purpose

To evaluate the patient’s positioning reproducibility during upright treatment with image-guided adaptive proton therapy (IGAPT) for head and neck cancers.

Materials and methods

10 head and neck (H&N) patients were treated with gantry-less IGAPT, which includes daily 3D computed tomography (CT) and two 2D kilovoltage radiographs before treatment and weekly 3DCT immediately after irradiation. All procedures were performed in the carbon chair on the 6 degrees of freedom robotic positioner.

Results

Prior to treatment we registered shifts in patient positioning using 3D/3D registration at the imaging isocenter: X  = -0.1 ± 3.9 (mean ± standard deviation) mm, Y = −3.7 ± 3.5 mm, Z = 0.5 ± 6.2 mm. The corresponding vector was applied to the robotic positioner to compensate for the registered shifts, after which the patients were moved to the treatment isocenter and the following shifts were obtained there using 2D/3D registration: X  = -0.31 ± 1.37 mm, Y = −0.02 ± 1.33 mm, Z = 0.59 ± 1.55 mm. Finally, the weekly follow-up 3D/3D registration showed X  = -0.2 ± 1.2 mm, Y = −0.0 ± 1.4 mm, Z = 2.3 ± 2.0 mm.

Conclusions

A novel image-guided gantry-less PT facility showed reliable results in terms of patient positioning for H&N cases during clinical trials. This fact confirmed the suitability of using gantry-less PT for H&N treatment. A small, systematic shift in the vertical direction was detected in the follow-up 3D/3D registration. The effect of this shift will be investigated in further studies with pre/post treatment 2D/3D registration. The next phase of the clinical trial of this facility is dedicated to the thorax region.
材料和方法 10 名头颈部(H&N)癌症患者接受了无龙门 IGAPT 治疗,其中包括治疗前的每日三维计算机断层扫描(CT)和两张二维千伏X光片,以及照射后的每周三维计算机断层扫描。所有手术均在碳纤维椅上的6自由度机器人定位器上进行:X=-0.1±3.9(平均值±标准差)毫米,Y=-3.7±3.5毫米,Z=0.5±6.2毫米。将相应的矢量应用于机器人定位器,以补偿登记的偏移,然后将患者移至治疗等中心,并使用二维/三维登记获得以下偏移:X = -0.31 ± 1.37 mm,Y = -0.02 ± 1.33 mm,Z = 0.59 ± 1.55 mm。最后,每周随访的三维/三维配准显示 X = -0.2 ± 1.2 mm,Y = -0.0 ± 1.4 mm,Z = 2.3 ± 2.0 mm。结论在临床试验中,一种新型的图像引导无龙门 PT 设备在 H&N 病例的患者定位方面显示出可靠的结果。这一事实证明了将无龙门 PT 用于 H&N 治疗的适宜性。在后续的三维/三维注册中,发现垂直方向有一个小的系统性偏移。这种偏移的影响将在进一步的研究中通过治疗前后的二维/三维登记进行调查。该设备下一阶段的临床试验将专门针对胸部区域。
{"title":"Study of upright patient positioning reproducibility in image-guided proton therapy for head and neck cancers","authors":"J. Feldman ,&nbsp;A. Pryanichnikov ,&nbsp;D. Shwartz ,&nbsp;Y. Hillman ,&nbsp;M. Wygoda ,&nbsp;P. Blumenfeld ,&nbsp;M. Marash ,&nbsp;A. Popovtzer","doi":"10.1016/j.radonc.2024.110572","DOIUrl":"10.1016/j.radonc.2024.110572","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the patient’s positioning reproducibility during upright treatment with image-guided adaptive proton therapy (IGAPT) for head and neck cancers.</div></div><div><h3>Materials and methods</h3><div>10 head and neck (H&amp;N) patients were treated with gantry-less IGAPT, which includes daily 3D computed tomography (CT) and two 2D kilovoltage radiographs before treatment and weekly 3DCT immediately after irradiation. All procedures were performed in the carbon chair on the 6 degrees of freedom robotic positioner.</div></div><div><h3>Results</h3><div>Prior to treatment we registered shifts in patient positioning using 3D/3D registration at the imaging isocenter: X  = -0.1 ± 3.9 (mean ± standard deviation) mm, Y = −3.7 ± 3.5 mm, Z = 0.5 ± 6.2 mm. The corresponding vector was applied to the robotic positioner to compensate for the registered shifts, after which the patients were moved to the treatment isocenter and the following shifts were obtained there using 2D/3D registration: X  = -0.31 ± 1.37 mm, Y = −0.02 ± 1.33 mm, Z = 0.59 ± 1.55 mm. Finally, the weekly follow-up 3D/3D registration showed X  = -0.2 ± 1.2 mm, Y = −0.0 ± 1.4 mm, Z = 2.3 ± 2.0 mm.</div></div><div><h3>Conclusions</h3><div>A novel image-guided gantry-less PT facility showed reliable results in terms of patient positioning for H&amp;N cases during clinical trials. This fact confirmed the suitability of using gantry-less PT for H&amp;N treatment. A small, systematic shift in the vertical direction was detected in the follow-up 3D/3D registration. The effect of this shift will be investigated in further studies with pre/post treatment 2D/3D registration. The next phase of the clinical trial of this facility is dedicated to the thorax region.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110572"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy? p16状态或对诱导化疗的反应,可预测接受确定性放疗的中国口咽癌患者的生存预后吗?
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110578
Ruichen Li , Yang Zhao , Kangting Wu, Huiqing Li, Xinru Lin, Liting Zhu, Yi Zhu, Xiaoshen Wang

Purpose

To identify whether p16 status or response to induction chemotherapy (IC) predicts the radiotherapy (RT) response and survival outcomes in Chinese oropharyngeal squamous cell carcinoma (OPSCC).

Methods

A total of 211 patients, including 128 p16-positive and 83 p16-negative were analyzed. All patients underwent IC followed by definitive RT or concurrent chemoradiotherapy (CCRT). Propensity score matching (PSM) was used to eliminate the baseline variations.

Results

Age, sex, smoking history, alcohol history, and primary site were unbalanced between different p16 status subgroups. Before PSM, the objective response rates to IC between p16-positive and p16-negative groups were 80.5 % and 85.5 % (p = 0.344). After RT, the complete response (CR) rates were 73.4 % and 66.3 %, respectively (p = 0.264). IC-sensitive (IC-s) subgroups had a higher percentage of RT-CR rate than the IC-resistant (IC-r) subgroups in both p16-positive and p16-negative patients. IC-s showed significant improvement in cancer-specific survival (CSS) (92.9 % vs. 53.6 %, p < 0.0001), progression-free survival (PFS) (p < 0.0001), locoregional relapse-free survival (LRFS) (p < 0.0001) and distant metastasis-free survival (DMFS) (p = 0.025). After PSM, the CR rates among different p16 groups remained comparable following RT (71.2 % vs. 65.8 %, p = 0.476). Before or after PSM, CSS, PFS, LRFS, and DMFS were similar between different p16 status either in IC-s or IC-r subgroups (p > 0.05). IC-r was independently associated with shorter PFS (HR = 2.661, p = 0.002) and LRFS (HR = 2.876, p = 0.002; HR = 2.78, p = 0.018).

Conclusions

Response to IC is an important predictor of prognosis in Chinese OPSCC treated with definitive RT. Poor response to IC is associated with unsatisfactory outcomes either in p16-positive or p16-negative OPSCC.
目的 确定p16状态或对诱导化疗(IC)的反应是否能预测中国口咽鳞癌(OPSCC)的放疗(RT)反应和生存结果。方法 对211例患者进行分析,包括128例p16阳性和83例p16阴性患者。所有患者均接受了IC治疗,随后接受了明确的RT或同期化放疗(CCRT)。结果 不同p16状态亚组之间的年龄、性别、吸烟史、酗酒史和原发部位不平衡。在 PSM 前,p16 阳性组和 p16 阴性组对 IC 的客观反应率分别为 80.5 % 和 85.5 %(p = 0.344)。RT 后,完全应答率(CR)分别为 73.4 % 和 66.3 %(p = 0.264)。在p16阳性和p16阴性患者中,IC敏感(IC-s)亚组的RT-CR率均高于IC耐药(IC-r)亚组。IC-s 在癌症特异性生存期(CSS)(92.9 % vs. 53.6 %,p < 0.0001)、无进展生存期(PFS)(p < 0.0001)、局部无复发生存期(LRFS)(p < 0.0001)和无远处转移生存期(DMFS)(p = 0.025)方面均有明显改善。在 PSM 之后,不同 p16 组别在 RT 之后的 CR 率仍然相当(71.2% vs. 65.8%,p = 0.476)。在 PSM 之前或之后,不同 p16 状态的 IC-s 或 IC-r 亚组的 CSS、PFS、LRFS 和 DMFS 相似(p > 0.05)。IC-r与较短的PFS(HR=2.661,P=0.002)和LRFS(HR=2.876,P=0.002;HR=2.78,P=0.018)独立相关。无论是p16阳性还是p16阴性的OPSCC,对IC反应差都与预后不理想有关。
{"title":"p16 status or response to induction chemotherapy, which predicts survival outcomes in Chinese oropharyngeal cancer treated with definitive radiotherapy?","authors":"Ruichen Li ,&nbsp;Yang Zhao ,&nbsp;Kangting Wu,&nbsp;Huiqing Li,&nbsp;Xinru Lin,&nbsp;Liting Zhu,&nbsp;Yi Zhu,&nbsp;Xiaoshen Wang","doi":"10.1016/j.radonc.2024.110578","DOIUrl":"10.1016/j.radonc.2024.110578","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify whether p16 status or response to induction chemotherapy (IC) predicts the radiotherapy (RT) response and survival outcomes in Chinese oropharyngeal squamous cell carcinoma (OPSCC).</div></div><div><h3>Methods</h3><div>A total of 211 patients, including 128 p16-positive and 83 p16-negative were analyzed. All patients underwent IC followed by definitive RT or concurrent chemoradiotherapy (CCRT). Propensity score matching (PSM) was used to eliminate the baseline variations.</div></div><div><h3>Results</h3><div>Age, sex, smoking history, alcohol history, and primary site were unbalanced between different p16 status subgroups. Before PSM, the objective response rates to IC between p16-positive and p16-negative groups were 80.5 % and 85.5 % (p = 0.344). After RT, the complete response (CR) rates were 73.4 % and 66.3 %, respectively (p = 0.264). IC-sensitive (IC-s) subgroups had a higher percentage of RT-CR rate than the IC-resistant (IC-r) subgroups in both p16-positive and p16-negative patients. IC-s showed significant improvement in cancer-specific survival (CSS) (92.9 % vs. 53.6 %, p &lt; 0.0001), progression-free survival (PFS) (p &lt; 0.0001), locoregional relapse-free survival (LRFS) (p &lt; 0.0001) and distant metastasis-free survival (DMFS) (p = 0.025). After PSM, the CR rates among different p16 groups remained comparable following RT (71.2 % vs. 65.8 %, p = 0.476). Before or after PSM, CSS, PFS, LRFS, and DMFS were similar between different p16 status either in IC-s or IC-r subgroups (p &gt; 0.05). IC-r was independently associated with shorter PFS (HR = 2.661, p = 0.002) and LRFS (HR = 2.876, p = 0.002; HR = 2.78, p = 0.018).</div></div><div><h3>Conclusions</h3><div>Response to IC is an important predictor of prognosis in Chinese OPSCC treated with definitive RT. Poor response to IC is associated with unsatisfactory outcomes either in p16-positive or p16-negative OPSCC.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110578"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost DBCG HYPO 试验中的乳房压痕和照射体积:年龄、吸烟和升压的影响
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110574
Mette S. Thomsen , Jan Alsner , Christina M. Lutz , Martin Berg , Ingelise Jensen , Ebbe L. Lorenzen , Hanne M. Nielsen , Erik H. Jakobsen , Lars Stenbygaard , Mette H. Nielsen , Maj-Britt Jensen , Jens Overgaard , Birgitte V. Offersen , on behalf of the DBCG RT Committee

Purpose

To investigate the association between irradiated breast volume and grade 2–3 breast induration three years after radiotherapy in the phase III Danish Breast Cancer Group HYPO trial randomizing patients ≥ 41 years to whole breast irradiation (WBI) with 40 Gy/15fr versus 50 Gy/25fr.

Methods

Treatment plans were available for all Danish patients. Associations between frequency of induration and irradiated volume, age, smoking status, and boost were assessed by logistic regression. A sequential boost was given to patients < 50 years or in case of a narrow (<2 mm) resection margin.

Results

RT plans from 1,333 patients were analyzed with 178 (13 %) having grade 2–3 induration. 1135 patients had only WBI. For this group, induration was correlated with irradiated breast volume for patients ≥ 65 years (n = 343, 10 %/22 % for small/large irradiated volumes, p = 0.005) but not for patients aged 50–64 years (n = 792, 11 % for both small and large volumes, p = 0.82). Smoking doubled the frequency irrespective of irradiated volume and age. All patients < 50 years (n = 156) had a boost. A volume effect was found for this group (5 %/21 % induration for small/large volume, p = 0.002). 42 patients ≥ 50 years had a boost and 14 (33 %) had grade 2–3 induration, however, with a p-value > 0.05 due to the few numbers of patients.

Conclusion

A relationship between irradiated breast volume and 3-year frequency of breast induration was found for patients ≥ 65 years, whilst not for patients aged 50–64 years. Smoking doubled the risk of induration irrespective of volume and age. A dose-induration relationship was seen for boost patients < 50 years.
目的在丹麦乳腺癌小组 HYPO III 期试验中,对年龄≥41 岁的患者随机进行 40 Gy/15fr 与 50 Gy/25fr 全乳腺照射(WBI),研究放疗三年后照射乳房体积与 2-3 级乳房压痕之间的关系。通过逻辑回归评估了压痕频率与照射体积、年龄、吸烟状况和增强剂量之间的关系。结果分析了1333名患者的治疗计划,其中178人(13%)有2-3级压痕。1135名患者只有WBI。在这组患者中,压痕与≥ 65 岁患者的照射乳房体积相关(n = 343,10%/22%为小/大照射体积,p = 0.005),但与 50-64 岁患者无关(n = 792,11%为小和大体积,p = 0.82)。无论照射量和年龄如何,吸烟都会使吸烟频率增加一倍。所有 50 岁及以上的患者(n = 156)的吸烟率都有所上升。在这组患者中发现了体积效应(体积小/体积大的压痕率分别为 5 %/21 %,p = 0.002)。42 名年龄≥50 岁的患者乳腺体积增大,14 名患者(33%)出现 2-3 级压痛,但由于患者人数较少,P 值为 0.05。无论乳房体积和年龄如何,吸烟都会使乳房硬化的风险增加一倍。在 50 岁以上的患者中,可以看到剂量与硬化的关系。
{"title":"Breast induration and irradiated volume in the DBCG HYPO trial: The impact of age, smoking, and boost","authors":"Mette S. Thomsen ,&nbsp;Jan Alsner ,&nbsp;Christina M. Lutz ,&nbsp;Martin Berg ,&nbsp;Ingelise Jensen ,&nbsp;Ebbe L. Lorenzen ,&nbsp;Hanne M. Nielsen ,&nbsp;Erik H. Jakobsen ,&nbsp;Lars Stenbygaard ,&nbsp;Mette H. Nielsen ,&nbsp;Maj-Britt Jensen ,&nbsp;Jens Overgaard ,&nbsp;Birgitte V. Offersen ,&nbsp;on behalf of the DBCG RT Committee","doi":"10.1016/j.radonc.2024.110574","DOIUrl":"10.1016/j.radonc.2024.110574","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate the association between irradiated breast volume and grade 2–3 breast induration three years after radiotherapy in the phase III Danish Breast Cancer Group HYPO trial randomizing patients ≥ 41 years to whole breast irradiation (WBI) with 40 Gy/15fr versus 50 Gy/25fr.</div></div><div><h3>Methods</h3><div>Treatment plans were available for all Danish patients. Associations between frequency of induration and irradiated volume, age, smoking status, and boost were assessed by logistic regression. A sequential boost was given to patients &lt; 50 years or in case of a narrow (&lt;2 mm) resection margin.</div></div><div><h3>Results</h3><div>RT plans from 1,333 patients were analyzed with 178 (13 %) having grade 2–3 induration. 1135 patients had only WBI. For this group, induration was correlated with irradiated breast volume for patients ≥ 65 years (n = 343, 10 %/22 % for small/large irradiated volumes, p = 0.005) but not for patients aged 50–64 years (n = 792, 11 % for both small and large volumes, p = 0.82). Smoking doubled the frequency irrespective of irradiated volume and age. All patients &lt; 50 years (n = 156) had a boost. A volume effect was found for this group (5 %/21 % induration for small/large volume, p = 0.002). 42 patients ≥ 50 years had a boost and 14 (33 %) had grade 2–3 induration, however, with a p-value &gt; 0.05 due to the few numbers of patients.</div></div><div><h3>Conclusion</h3><div>A relationship between irradiated breast volume and 3-year frequency of breast induration was found for patients ≥ 65 years, whilst not for patients aged 50–64 years. Smoking doubled the risk of induration irrespective of volume and age. A dose-induration relationship was seen for boost patients &lt; 50 years.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110574"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transit-guided radiation therapy: a novel patient monitoring approach 中转引导放射治疗:一种新型患者监测方法
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110580
Artur Latorre-Musoll , Gabriela Oses , Gabriela Antelo , Sergi Serrano-Rueda , Meritxell Mollà , Josep Sempau , Núria Jornet

Background and purpose

Transit-Guided Radiation Therapy (TGRT) is a novel technique that uses the transit portal images (TPIs) acquired with Electronic Portal Image Devices (EPID) to quantify patient position errors during the treatment. It has been validated using anthropomorphic phantoms but a validation in a clinical setting was lacking. A pilot clinical study is presented to confirm our previous results.

Materials and methods

A prospective study was conducted between June and December 2022 with patients who received whole-brain or breast radiotherapy treatments. The selected treatments were composed of radiation fields using skin-flash, where the body contour projected a sharp edge on the EPID which has been used as a surrogate of the true patient position. Daily imaging procedures were applied as scheduled before running the one- and two-parameter model (1PM and 2PM) of the TGRT formalism on the acquired TPIs to independently estimate the patient position errors.

Results

43 patients and 1015 TPIs have been assessed. The 2PM showed a better correlation with the true position errors (R2 = 0.76 vs. 0.73), a lower detection threshold (0.77 mm vs. 1.24 mm), and a lower overcorrection risk above the detection threshold (7.0 % vs. 11.1 %) than the 1PM. Overall, the 2PM would have significantly reduced the true position errors by a factor of 0.58 (0.49 – 1.27) (p < 0.0001).

Conclusion

The TGRT technique has confirmed the ability to reduce the position errors in a clinical setting, demonstrating the potential to enhance the patient position monitoring without increasing treatment time or patient dose.
背景和目的经门静脉引导放射治疗(TGRT)是一项新技术,它利用电子经门静脉图像装置(EPID)获取的经门静脉图像(TPI)来量化治疗过程中患者的位置误差。该技术已通过拟人化模型验证,但在临床环境中还缺乏验证。材料和方法 2022 年 6 月至 12 月期间,我们对接受全脑或乳腺放疗的患者进行了前瞻性研究。所选治疗由使用皮肤闪光的辐射场组成,身体轮廓在 EPID 上投射出锐利的边缘,EPID 被用作患者真实位置的替代物。在对获得的 TPIs 运行 TGRT 形式的单参数和双参数模型(1PM 和 2PM)之前,按计划进行每日成像程序,以独立估计患者位置误差。与 1PM 相比,2PM 与真实位置误差的相关性更好(R2 = 0.76 对 0.73),检测阈值更低(0.77 mm 对 1.24 mm),超过检测阈值的过度校正风险更低(7.0 % 对 11.1 %)。总的来说,2PM 能将真实位置误差显著降低 0.58(0.49 - 1.27)倍(p < 0.0001)。结论TGRT 技术已证实能在临床环境中减少位置误差,证明了在不增加治疗时间或患者剂量的情况下加强患者位置监测的潜力。
{"title":"Transit-guided radiation therapy: a novel patient monitoring approach","authors":"Artur Latorre-Musoll ,&nbsp;Gabriela Oses ,&nbsp;Gabriela Antelo ,&nbsp;Sergi Serrano-Rueda ,&nbsp;Meritxell Mollà ,&nbsp;Josep Sempau ,&nbsp;Núria Jornet","doi":"10.1016/j.radonc.2024.110580","DOIUrl":"10.1016/j.radonc.2024.110580","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Transit-Guided Radiation Therapy (TGRT) is a novel technique that uses the transit portal images (TPIs) acquired with Electronic Portal Image Devices (EPID) to quantify patient position errors during the treatment. It has been validated using anthropomorphic phantoms but a validation in a clinical setting was lacking. A pilot clinical study is presented to confirm our previous results.</div></div><div><h3>Materials and methods</h3><div>A prospective study was conducted between June and December 2022 with patients who received whole-brain or breast radiotherapy treatments. The selected treatments were composed of radiation fields using skin-flash, where the body contour projected a sharp edge on the EPID which has been used as a surrogate of the true patient position. Daily imaging procedures were applied as scheduled before running the one- and two-parameter model (1PM and 2PM) of the TGRT formalism on the acquired TPIs to independently estimate the patient position errors.</div></div><div><h3>Results</h3><div>43 patients and 1015 TPIs have been assessed. The 2PM showed a better correlation with the true position errors (<em>R</em><sup>2</sup> = 0.76 vs. 0.73), a lower detection threshold (0.77 mm vs. 1.24 mm), and a lower overcorrection risk above the detection threshold (7.0 % vs. 11.1 %) than the 1PM. Overall, the 2PM would have significantly reduced the true position errors by a factor of 0.58 (0.49 – 1.27) (<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>The TGRT technique has confirmed the ability to reduce the position errors in a clinical setting, demonstrating the potential to enhance the patient position monitoring without increasing treatment time or patient dose.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110580"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142446946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A model-based risk-minimizing proton treatment planning concept for brain injury prevention in low-grade glioma patients 基于模型的风险最小化质子治疗规划概念,用于预防低级别胶质瘤患者的脑损伤。
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110579
H. Sallem , S. Harrabi , E. Traneus , K. Herfarth , J. Debus , J. Bauer

Purpose

Late-occurring contrast-enhancing brain lesions (CEBLs) have been observed on MRI follow-up in low-grade glioma (LGG) patients post-proton therapy. Predictive risk-models for this endpoint identified a dose-averaged linear energy transfer (LETd)-dependent proton relative biological effectiveness (RBE) effect on CEBL occurrence and increased radiosensitivity of the cerebral periventricular region (VP4mm). This work aimed to design a stable risk-minimizing treatment planning (TP) concept addressing these intertwined risk factors through a classically formulated optimization problem.

Material and methods

The concept was developed in RayStation-research 11B IonPG featuring a variable-RBE-based optimizer involving 20 LGG patients with varying target volume localizations and risk-factor contributions. Classical cost functions penalizing dose, dose-volume-histogram points, and equivalent uniform dose were used to formulate the optimization problem, and a new set of structures was introduced to actively spare the VP4mm, control high LETd regions, and de-escalate the dose outside the gross tumor volume. Target volume coverage and organ-at-risk sparing were robustly evaluated, and Normal Tissue Complication Probabilities (NTCP) for CEBL occurrence were quantified.

Results

The concept yielded stable optimization outcomes for all considered subjects. Risk hot spots were successfully mitigated, and an NTCP reduction of up to 79 % was observed compared to conventional TP while maintaining target coverage, demonstrating the feasibility of the chosen model-based approach.

Conclusion

With the proposed TP protocol, we close the gap between predictive risk-modeling and practical risk-mitigation in the clinic and provide a concept for CEBL avoidance with the potential to advance treatment precision for LGG patients.
目的:在质子治疗后对低级别胶质瘤(LGG)患者进行磁共振成像随访时,发现了晚期出现的对比增强脑病变(CEBL)。针对这一终点的预测性风险模型确定了质子相对生物效应(RBE)对CEBL发生的剂量平均线性能量转移(LETd)依赖效应,以及脑室周围区域(VP4mm)放射敏感性的增加。这项工作旨在设计一种稳定的风险最小化治疗计划(TP)概念,通过经典的优化问题来解决这些相互交织的风险因素:该概念是在 RayStation-research 11B IonPG 中开发的,其特点是基于可变 RBE 的优化器,涉及 20 名 LGG 患者,其靶体积定位和风险因素贡献各不相同。在制定优化问题时,使用了惩罚剂量、剂量-体积-柱状图点和等效均匀剂量的经典成本函数,并引入了一套新的结构,以主动切除 VP4mm、控制高 LETd 区域并降低肿瘤总体积外的剂量。对靶体积覆盖率和危险器官疏通进行了稳健评估,并量化了CEBL发生的正常组织并发症概率(NTCP):结果:该概念为所有受试者带来了稳定的优化结果。在保持目标覆盖率的同时,风险热点得到了成功缓解,与传统 TP 相比,NTCP 降低了 79%,这证明了所选基于模型方法的可行性:通过提出的 TP 方案,我们缩小了预测性风险建模与临床实际风险缓解之间的差距,并提供了一种避免 CEBL 的概念,有望提高 LGG 患者的治疗精度。
{"title":"A model-based risk-minimizing proton treatment planning concept for brain injury prevention in low-grade glioma patients","authors":"H. Sallem ,&nbsp;S. Harrabi ,&nbsp;E. Traneus ,&nbsp;K. Herfarth ,&nbsp;J. Debus ,&nbsp;J. Bauer","doi":"10.1016/j.radonc.2024.110579","DOIUrl":"10.1016/j.radonc.2024.110579","url":null,"abstract":"<div><h3>Purpose</h3><div>Late-occurring contrast-enhancing brain lesions (CEBLs) have been observed on MRI follow-up in low-grade glioma (LGG) patients post-proton therapy. Predictive risk-models for this endpoint identified a dose-averaged linear energy transfer (LET<sub>d</sub>)-dependent proton relative biological effectiveness (RBE) effect on CEBL occurrence and increased radiosensitivity of the cerebral periventricular region (VP<sub>4mm</sub>). This work aimed to design a stable risk-minimizing treatment planning (TP) concept addressing these intertwined risk factors through a classically formulated optimization problem.</div></div><div><h3>Material and methods</h3><div>The concept was developed in RayStation-research 11B IonPG featuring a variable-RBE-based optimizer involving 20 LGG patients with varying target volume localizations and risk-factor contributions. Classical cost functions penalizing dose, dose-volume-histogram points, and equivalent uniform dose were used to formulate the optimization problem, and a new set of structures was introduced to actively spare the VP<sub>4mm</sub>, control high LET<sub>d</sub> regions, and de-escalate the dose outside the gross tumor volume. Target volume coverage and organ-at-risk sparing were robustly evaluated, and Normal Tissue Complication Probabilities (NTCP) for CEBL occurrence were quantified.</div></div><div><h3>Results</h3><div>The concept yielded stable optimization outcomes for all considered subjects. Risk hot spots were successfully mitigated, and an NTCP reduction of up to 79 % was observed compared to conventional TP while maintaining target coverage, demonstrating the feasibility of the chosen model-based approach.</div></div><div><h3>Conclusion</h3><div>With the proposed TP protocol, we close the gap between predictive risk-modeling and practical risk-mitigation in the clinic and provide a concept for CEBL avoidance with the potential to advance treatment precision for LGG patients.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110579"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect 用三元分类法预测个体疗效,指导局部晚期鼻咽癌的诱导化疗。
IF 4.9 1区 医学 Q1 ONCOLOGY Pub Date : 2024-10-10 DOI: 10.1016/j.radonc.2024.110571
Zhiying Liang , Chao Luo , Shuqi Li , Yuliang Zhu , Wenjie Huang , Di Cao , Yifei Liu , Guangying Ruan , Shaobo Liang , Xi Chen , Kit-Ian Kou , Guoyi Zhang , Lizhi Liu , Haojiang Li

Background and purpose

Induction chemotherapy (IC) before concurrent chemoradiotherapy does not universally improve long-term overall survival (OS) in locoregionally advanced nasopharyngeal carcinoma (LANPC). Conventional risk stratification often yields suboptimal IC decisions. Our study introduces a ternary classification of predicted individual treatment effect (PITE) to guide personalized IC decisions.

Materials and methods

A two-center retrospective analysis of 1,213 patients with LANPC was conducted to develop and validate prognostic models integrating magnetic resonance imaging and clinical data to estimate individual 5-year OS probabilities for IC and non-IC treatments. Differences in these probabilities defined PITE, facilitating patient stratification into three IC recommendation categories. Model effectiveness was validated using Kaplan–Meier estimators, decision curve-like analysis, and evaluations of variable importance and distribution.

Results

The models exhibited strong predictive performance in both treatments across training and cross-validation sets, enabling accurate PITE calculations and patient classification. Compared with non-IC treatment, IC markedly improved OS in the IC-preferred group (HR = 0.62, p = 0.02), had no effect in the IC-neutral group (HR = 1.00, p = 0.70), and worsened OS in the IC-opposed group (HR = 2.00, p = 0.03). The ternary PITE classification effectively identified 41.7 % of high-risk patients not benefiting from IC, and yielded a 2.68 % higher mean 5-year OS probability over risk-based decisions. Significantly increasing distributions of key prognostic indicators, such as metastatic lymph node number and plasma Epstein–Barr virus DNA level from IC-opposed to IC-preferred groups, further validated the clinical relevance of PITE classification.

Conclusion

The ternary PITE classification offers an accurate and clinically advantageous approach to guide personalized IC decision-making in patients with LANPC.
背景和目的:对于局部区域性晚期鼻咽癌(LANPC),在同时进行化放疗之前先进行诱导化疗(IC)并不能普遍提高长期总生存率(OS)。传统的风险分层通常会产生次优化疗决策。我们的研究引入了预测个体治疗效果(PITE)的三元分类法,以指导个性化的IC决策:我们在两个中心对 1,213 名 LANPC 患者进行了回顾性分析,开发并验证了整合磁共振成像和临床数据的预后模型,以估计 IC 和非 IC 治疗的个体 5 年 OS 概率。这些概率的差异定义了 PITE,有助于将患者分为三个 IC 推荐类别。使用 Kaplan-Meier 估计器、决策曲线分析以及变量重要性和分布评估验证了模型的有效性:结果:在训练集和交叉验证集上,模型对两种治疗方法都表现出很强的预测能力,能够准确计算 PITE 和对患者进行分类。与非 IC 治疗相比,IC 首选组的 OS 明显改善(HR = 0.62,p = 0.02),IC 中立组无影响(HR = 1.00,p = 0.70),而 IC 反对组的 OS 则恶化(HR = 2.00,p = 0.03)。PITE 三元分类法能有效识别出 41.7% 的高危患者无法从 IC 中获益,其 5 年平均 OS 概率比基于风险的决策高出 2.68%。关键预后指标(如转移性淋巴结数量和血浆 Epstein-Barr 病毒 DNA 水平)的分布明显增加,进一步验证了 PITE 分类的临床相关性:结论:三元 PITE 分类为指导 LANPC 患者的个性化 IC 决策提供了一种准确且具有临床优势的方法。
{"title":"Guiding induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma with ternary classification of predicted individual treatment effect","authors":"Zhiying Liang ,&nbsp;Chao Luo ,&nbsp;Shuqi Li ,&nbsp;Yuliang Zhu ,&nbsp;Wenjie Huang ,&nbsp;Di Cao ,&nbsp;Yifei Liu ,&nbsp;Guangying Ruan ,&nbsp;Shaobo Liang ,&nbsp;Xi Chen ,&nbsp;Kit-Ian Kou ,&nbsp;Guoyi Zhang ,&nbsp;Lizhi Liu ,&nbsp;Haojiang Li","doi":"10.1016/j.radonc.2024.110571","DOIUrl":"10.1016/j.radonc.2024.110571","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Induction chemotherapy (IC) before concurrent chemoradiotherapy does not universally improve long-term overall survival (OS) in locoregionally advanced nasopharyngeal carcinoma (LANPC). Conventional risk stratification often yields suboptimal IC decisions. Our study introduces a ternary classification of predicted individual treatment effect (PITE) to guide personalized IC decisions.</div></div><div><h3>Materials and methods</h3><div>A two-center retrospective analysis of 1,213 patients with LANPC was conducted to develop and validate prognostic models integrating magnetic resonance imaging and clinical data to estimate individual 5-year OS probabilities for IC and non-IC treatments. Differences in these probabilities defined PITE, facilitating patient stratification into three IC recommendation categories. Model effectiveness was validated using Kaplan–Meier estimators, decision curve-like analysis, and evaluations of variable importance and distribution.</div></div><div><h3>Results</h3><div>The models exhibited strong predictive performance in both treatments across training and cross-validation sets, enabling accurate PITE calculations and patient classification. Compared with non-IC treatment, IC markedly improved OS in the IC-preferred group (HR = 0.62, p = 0.02), had no effect in the IC-neutral group (HR = 1.00, p = 0.70), and worsened OS in the IC-opposed group (HR = 2.00, p = 0.03). The ternary PITE classification effectively identified 41.7 % of high-risk patients not benefiting from IC, and yielded a 2.68 % higher mean 5-year OS probability over risk-based decisions. Significantly increasing distributions of key prognostic indicators, such as metastatic lymph node number and plasma Epstein–Barr virus DNA level from IC-opposed to IC-preferred groups, further validated the clinical relevance of PITE classification.</div></div><div><h3>Conclusion</h3><div>The ternary PITE classification offers an accurate and clinically advantageous approach to guide personalized IC decision-making in patients with LANPC.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"201 ","pages":"Article 110571"},"PeriodicalIF":4.9,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Radiotherapy and Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1